Intest Res.  2022 Jul;20(3):381-385. 10.5217/ir.2021.00073.

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis

• O’Connell J
• Doherty J
• Buckley A
• Cormican D
• Dunne C
• Hartery K
• Larkin J
• MacCarthy F
• McCormick P
• McKiernan S
• Mehigan B
• Muldoon C
• Ryan C
• O’Sullivan J
• Kevans D

• KMID: 2531992
• DOI: http://doi.org/10.5217/ir.2021.00073

Figure

• 

  Fig. 1. Association between oncostatin M (OSM) immunostaining colectomy-free survival. Kaplan-Meir survival curves describing colectomy-free survival in low and high OSM immunostaining groups. Panels show survival analysis for epithelial OSM percentage staining (A), epithelial OSM staining intensity (B), stromal OSM percentage staining (C), and stromal OSM staining intensity (D), respectively. One subject in the study cohort did not have data on time to colectomy available and was excluded from analyses.

• 

  Fig. 2. Association between epithelial oncostatin M (OSM) immunostaining intensity and C-reactive protein (CRP) (A) and CRP/albumin ratio (B).

Reference

1. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2002; 16 Suppl 4:7–12.

2. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017; 11:769–784.

3. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5:103–110.

4. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016; 1:15–24.

5. Beigel F, Friedrich M, Probst C, et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PLoS One. 2014; 9:e93498.

6. West NR, Hegazy AN, Owens BM, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017; 23:579–589.

7. Verstockt S, Verstockt B, Machiels K, et al. Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease. Inflamm Bowel Dis. 2021; 27:1564–1575.

8. Gibson DJ, Hartery K, Doherty J, et al. CRP/albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol. 2018; 52:e48–e52.

9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462–2476.

10. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146:85–95.